Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.37 |
| ▸ | CCR2 | P41597 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MMP1 | P03956 | 1/20 | 0.33 |
| ▸ | MMP9 | P14780 | 1/20 | 0.33 |
| ▸ | MMP13 | P45452 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL16895224 | 0.98 | CYP2C19 (0.37) | CYP2C19MAPTPOLBTDP1DGAT1 | |
| SCHEMBL8201537 | 0.92 | MAPT (0.37) | CYP2C19MAPTPOLBTDP1DGAT1 | |
| SCHEMBL26135944 | 0.86 | CCR2 (0.38) | CYP2C19MAPTPOLBTDP1CCR2 | |
| SCHEMBL27412775 | 0.84 | MAPT (0.41) | CYP2C19MAPTPOLBTDP1DGAT1 | |
| Ammonia Solution, Strong SCHEMBL16982684 | 0.82 | MAPT (0.40) | CYP2C19MAPTPOLBTDP1DGAT1 | |
| SCHEMBL9247025 | 0.82 | CCR2 (0.33) | CCR2ALDH1A1TSHR | |
| SCHEMBL3181055 | 0.82 | CYP2C19 (0.38) | CYP2C19MAPTPOLBTDP1DGAT1 | |
| SCHEMBL4453702 | 0.80 | CCR2 (0.36) | MAPTCCR2ALDH1A1TSHR | |
| SCHEMBL545208 | 0.80 | CCR2 (0.32) | CCR2 | |
| SCHEMBL17666352 | 0.80 | ALDH1A1 (0.38) | CYP2C19MAPTPOLBTDP1DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 190 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109761810-B | Preparation method of inactive alkene aryl compound | 浙江工业大学 | 2021-07-27 | — | — | CN | claimed |
| US-20160046885-A1 | BRANCHED POLYMERS AS VISCOSITY AND/OR FRICTION MODIFIERS FOR LUBRICANTS | BATTELLE MEMORIAL INSTITUTE (US) | 2016-02-18 | — | — | US | claimed |
| US-12577251-B2 | Modulators of the sigma-2 receptor and their method of use | Temple University—Of the Commonwealth System of Higher Education (US) | 2026-03-17 | — | — | US | disclosed |
| EP-3200589-B1 | NOVEL 5-HYDROXYTRYPTAMINE RECEPTOR 7 ACTIVITY MODULATORS AND THEIR METHOD OF USE | UNIV TEMPLE (US) | 2026-03-11 | — | — | EP | disclosed |
| US-12503458-B2 | 5-hydroxytryptamine receptor 7 activity modulators and their method of use | TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2025-12-23 | — | — | US | disclosed |
| US-12338245-B2 | 5-hydroxytryptamine receptor 7 modulators and their use as therapeutic agents | Temple University—Of the Commonwealth System of Higher Education (US) | 2025-06-24 | — | — | US | disclosed |
| EP-3600290-B1 | NOVEL MODULATORS OF THE SIGMA-2 RECEPTOR AND THEIR METHOD OF USE | UNIV TEMPLE (US) | 2025-06-04 | — | — | EP | disclosed |
| CN-119798491-A | Coordination precipitation polymerization process for olefin polymerization and polyolefin | 中国石油化工股份有限公司 | 2025-04-11 | — | — | CN | disclosed |
| US-12269809-B2 | 5-hydroxytryptamine receptor 7 activity modulators and their method of use | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2025-04-08 | — | — | US | disclosed |
| CN-119661750-A | Coordination precipitation polymerization process for olefin polymerization and polyolefin | 中国石油化工股份有限公司 | 2025-03-21 | — | — | CN | disclosed |
| US-20250042894-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | CALICO LIFE SCIENCES LLC | 2025-02-06 | — | — | US | disclosed |
| EP-0998504-A1 | POLYMERIZATION OF OLEFINS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2000-05-10 | — | — | EP | disclosed |
| WO-1999005189-A1 | POLYMERIZATION OF OLEFINS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1999-02-04 | — | — | WO | disclosed |
| EP-0059756-B1 | 7-OXOPROSTACYCLIN DERIVATIVES AND PROCESS FOR THE PREPARATION THEREOF | SCHERING AKTIENGESELLSCHAFT (DE) | 1985-08-28 | — | — | EP | disclosed |
| US-4489092-A | Prostanoic acid derivatives and their preparation | SCHERING AKTIENGESELLSCHAFT (DE) | 1984-12-18 | — | — | US | disclosed |
| US-4466969-A | 7-Oxoprostacyclin derivatives and their use as hypotensives and bronchodilators | SCHERING AKTIENGESELLSCHAFT (DE) | 1984-08-21 | — | — | US | disclosed |
| US-4359467-A | Prostanoic acid derivatives and their preparation | SCHERING AKTIENGESELLSCHAFT (DE) | 1982-11-16 | — | — | US | disclosed |
| EP-0059756-A1 | 7-OXOPROSTACYCLIN DERIVATIVES AND PROCESS FOR THE PREPARATION THEREOF. | SCHERING AG (DE) | 1982-09-15 | — | — | EP | disclosed |
| WO-1982001002-A1 | 7-OXOPROSTACYCLIN DERIVATIVES AND PROCESS FOR THE PREPARATION THEREOF | NICKOLSON R | 1982-04-01 | — | — | WO | disclosed |
| US-4284646-A | Prostanoic acid derivatives and their preparation | SCHERING AKTIENGESELLSCHAFT (DE) | 1981-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12503458-B2 | 5-hydroxytryptamine receptor 7 activity modulators and their method of use | HTR7, HTR5A, HTR6 | CYP2C19 847/4885MAPT 1051/4885POLB 3738/4885 |
| US-20250042894-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | PTPN1, PTPN5, PTPN18 | CYP2C19 1839/4885MAPT 4492/4885POLB 4752/4885 |
| US-12338245-B2 | 5-hydroxytryptamine receptor 7 modulators and their use as therapeutic agents | HTR7, HTR6, HTR5A | CYP2C19 1509/4885MAPT 912/4885POLB 4342/4885 |
| US-12269809-B2 | 5-hydroxytryptamine receptor 7 activity modulators and their method of use | HTR7, HTR5A, HTR6 | CYP2C19 847/4885MAPT 1051/4885POLB 3738/4885 |
| US-12577251-B2 | Modulators of the sigma-2 receptor and their method of use | SIGMAR1, CHRNA6, NR3C2 | CYP2C19 528/4885MAPT 4325/4885POLB 1676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.